Wyeth: The leader in women's health—yesterday, today, and tomorrow

Forward looking statement This article includes statements of historical fact as well as projections about the future. Projections about the future are based on the best information available today, but involve significant risks and uncertainties. In the pharmaceutical industry, few products move successfully through all three stages of clinical development, and fewer still achieve regulatory approval. Also, some of the uses for which a product is investigated may not be supported by the clinical data, and/or may not be approved by the regulatory authorities. Therefore, there is no guarantee that pharmaceutical products in development will be approved as projected and introduced commercially. Wyeth Pharmaceuticals (“the Company”) assumes no obligation to update the projections in this article. Individuals are advised to refer to the statements filed by the Company with the Securities and Exchange Commission for the most current information.

As the leader in women's health care for more than 60 years, Wyeth remains committed to developing new and innovative treatments and improving the lives of women worldwide. Wyeth's Women's Health Research Institute^® is the only institute in the pharmaceutical industry dedicated solely to research in women's health. The strength of Wyeth's commitment to research and development is evident in its participation in landmark clinical trials and in the depth and breadth of its current and future products. Recently launched products include low-dose conjugated estrogens (CE) and low-dose CE/medroxyprogesterone acetate (MPA) postmenopausal hormone therapies. Wyeth's goal is to develop new products that offer clear clinical advantages over existing therapies in terms of product safety and/or efficacy. The pipeline of women's health products includes several innovative products that have the potential to be either first-in-class or best-in-class. The future product pipeline includes a non-hormonal option for the treatment of hot flushes, a selective estrogen receptor modulator (SERM) for the prevention and treatment of osteoporosis, a new drug paradigm that combines a SERM with conjugated estrogens (CE) for the treatment of conditions related to the menopause, and oral contraceptives (OCs), including a low-dose continuous regimen and the first non-steroidal formulation. Many other innovative women's health products are in earlier stages of development, including a novel treatment for endometriosis.